ZEG.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:35):

Stats
Dagens volum	28 324.00
Gjennomsnittsvolum	60 430.00
Markedsverdi	217.50B
EPS	€0.881 ( 2023-09-30 )
Last Dividend	€0.718 ( 2023-08-10 )
Next Dividend	€0 ( N/A )
P/E	37.12
ATR14	€0.120 (0.09%)

Volum Korrelasjon

Lang: -0.13 (neutral)

Kort: -0.16 (neutral)

Signal:(64.38) Neutral

AstraZeneca PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

AstraZeneca PLC Korrelasjon - Valuta/Råvare

0.01
( neutral )

-0.27
( neutral )

0.00
( neutral )

0.44
( neutral )

-0.27
( neutral )

0.53
( weak )

AstraZeneca PLC Økonomi

Annual	2023
Omsetning:	€45.81B
Bruttogevinst:	€37.54B (81.95 %)
EPS:	€3.84

FY	2023
Omsetning:	€45.81B
Bruttogevinst:	€37.54B (81.95 %)
EPS:	€3.84

FY	2022
Omsetning:	€44.35B
Bruttogevinst:	€31.96B (72.06 %)
EPS:	€2.12

FY	2021
Omsetning:	€37.42B
Bruttogevinst:	€24.98B (66.76 %)
EPS:	€0.0800

Financial Reports:

No articles found.

AstraZeneca PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0.764 (N/A)	€0 (N/A)	€1.628 (N/A)	€0 (N/A)	€0.718 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

AstraZeneca PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.67 - Stable (33.38%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.540	2004-02-18
Last Dividend	€0.718	2023-08-10
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	40	--
Total Paid Out	€40.56	--
Avg. Dividend % Per Year	0.00%	--
Score	3.91	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.67
Div. Directional Score	8.37	--

Next Divdend (Est)
(2024-07-01)

€0.686 Estimate 7.53 %

Dividend Stability

0.30 Poor

Dividend Score

3.91

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
GKS.DE	Ex Dividend Junior	2023-06-29	Sporadic	0.00%
PSG.DE	Ex Dividend Knight	2023-06-29	Annually	0.00%
BIJ.DE	Ex Dividend Knight	2023-06-21	Sporadic	0.00%
IE2A.F	Ex Dividend Junior	2023-05-02	Sporadic	0.00%
SOW.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
CRZK.DE	Ex Dividend Junior	2023-07-17	Annually	0.00%
LLD.DE	Ex Dividend Junior	2023-08-03	Annually	0.00%
1U1.DE	Ex Dividend Junior	2023-05-17	Annually	0.00%
UWS.DE	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
EIN3.DE	Ex Dividend Knight	2023-06-26	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.130	1.500	7.40	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0589	1.200	8.04	9.64	[0 - 0.3]
returnOnEquityTTM	0.159	1.500	9.34	10.00	[0.1 - 1]
payoutRatioTTM	0.752	-1.000	2.48	-2.48	[0 - 1]
currentRatioTTM	0.820	0.800	-0.898	-0.719	[1 - 3]
quickRatioTTM	0.467	0.800	-1.958	-1.566	[0.8 - 2.5]
cashRatioTTM	0.191	1.500	-0.0488	-0.0732	[0.2 - 2]
debtRatioTTM	0.283	-1.500	5.28	-7.92	[0 - 0.6]
interestCoverageTTM	5.13	1.000	9.21	9.21	[3 - 30]
operatingCashFlowPerShareTTM	6.62	2.00	7.79	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.20	2.00	7.90	10.00	[0 - 20]
debtEquityRatioTTM	0.731	-1.500	7.08	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.179	1.000	8.42	8.42	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.361	1.000	9.10	9.10	[0.2 - 2]
assetTurnoverTTM	0.453	0.800	-0.313	-0.250	[0.5 - 2]
Total Score				10.08

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.38	1.000	6.12	0	[1 - 100]
returnOnEquityTTM	0.159	2.50	9.58	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.20	2.00	8.60	10.00	[0 - 30]
dividendYielPercentageTTM	1.518	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.62	2.00	7.79	10.00	[0 - 30]
payoutRatioTTM	0.752	1.500	2.48	-2.48	[0 - 1]
pegRatioTTM	2.99	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.226	1.000	6.85	0	[0.1 - 0.5]
Total Score				6.67

AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.